| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1034/J.1399-3038.1999.00006.X |
| P698 | PubMed publication ID | 10478608 |
| P2093 | author name string | Schuster A | |
| García-Marcos L | |||
| P2860 | cites work | The release of histamine and formation of a slow-reacting substance (SRS-A) during anaphylactic shock | Q24537753 |
| Role of leukotrienes in exercise-induced asthma. Inhibitory effect of ICI 204219, a potent leukotriene D4 receptor antagonist | Q28319336 | ||
| Lung function improvement in asthma with a cysteinylleukotriene receptor antagonist | Q28322631 | ||
| Leukotriene C: a slow-reacting substance from murine mastocytoma cells | Q33972104 | ||
| Liberation of histamine and formation of lysocithin-like substances by cobra venom | Q34568156 | ||
| Leukotriene antagonists and synthesis inhibitors: new directions in asthma therapy | Q34734391 | ||
| The leukotriene receptor antagonist zafirlukast inhibits sulfur dioxide-induced bronchoconstriction in patients with asthma | Q34743993 | ||
| Zafirlukast. A review of its pharmacology and therapeutic potential in the management of asthma | Q34745153 | ||
| Inhibition of exercise-induced bronchospasm by zileuton: a 5-lipoxygenase inhibitor | Q71078790 | ||
| Challenge interval determines tachyphylaxis to aerosolized LTD4 | Q71562944 | ||
| Effect of chronic 5-lipoxygenase inhibition on airway hyperresponsiveness in asthmatic subjects | Q71723668 | ||
| Acute and chronic effects of a 5-lipoxygenase inhibitor in asthma: a 6-month randomized multicenter trial. Zileuton Study Group | Q71823499 | ||
| Effect of 5-lipoxygenase inhibition on bronchoconstriction and airway inflammation in nocturnal asthma | Q72032630 | ||
| The effect of inhibition of 5-lipoxygenase by zileuton in mild-to-moderate asthma | Q72605042 | ||
| Inhaled ICI 204,219 blocks antigen-induced bronchoconstriction in subjects with bronchial asthma | Q72770103 | ||
| The single and multiple dose pharmacokinetics of pranlukast in healthy volunteers | Q73018027 | ||
| Montelukast causes prolonged, potent leukotriene D4-receptor antagonism in the airways of patients with asthma | Q73047675 | ||
| Leukotriene antagonist prevents exacerbation of asthma during reduction of high-dose inhaled corticosteroid. The Tokyo Joshi-Idai Asthma Research Group | Q73227877 | ||
| The effect of inhaled leukotriene D4 and methacholine on sputum cell differentials in asthma | Q73227888 | ||
| Pharmacokinetics of zileuton and its metabolites in patients with renal impairment | Q73349032 | ||
| Urinary leukotriene E4 levels in patients with atopic dermatitis | Q73471560 | ||
| Results of the first U.S. double-blind, placebo-controlled, multicenter clinical study in asthma with pranlukast, a novel leukotriene receptor antagonist | Q73570827 | ||
| A randomized controlled trial comparing zileuton with theophylline in moderate asthma. The Zileuton Study Group | Q74113179 | ||
| Montelukast for chronic asthma in 6- to 14-year-old children: a randomized, double-blind trial. Pediatric Montelukast Study Group | Q74471633 | ||
| Montelukast, a once-daily leukotriene receptor antagonist, in the treatment of chronic asthma: a multicenter, randomized, double-blind trial. Montelukast Clinical Research Study Group | Q74643437 | ||
| Montelukast, a leukotriene-receptor antagonist, for the treatment of mild asthma and exercise-induced bronchoconstriction | Q74777695 | ||
| Effects of montelukast (MK-0476); a potent cysteinyl leukotriene receptor antagonist, on bronchodilation in asthmatic subjects treated with and without inhaled corticosteroids | Q35563114 | ||
| Effect of pranlukast, an oral leukotriene receptor antagonist, on leukotriene D4 (LTD4) challenge in normal volunteers | Q35563630 | ||
| Pranlukast, a novel leukotriene receptor antagonist: results of the first European, placebo controlled, multicentre clinical study in asthma | Q35563656 | ||
| Effect of a leukotriene B4 receptor antagonist, LY293111, on allergen induced responses in asthma | Q36504441 | ||
| Leukotrienes and airway responses. | Q39144237 | ||
| In vitro and in vivo effects of leukotriene B4 antagonism in a primate model of asthma | Q39758020 | ||
| Cysteinyl leukotrienes in asthma: old mediators up to new tricks | Q40372475 | ||
| Pulmonary infiltrates, eosinophilia, and cardiomyopathy following corticosteroid withdrawal in patients with asthma receiving zafirlukast | Q40642085 | ||
| Inhibition of leukotriene D4-induced bronchoconstriction in normal subjects by the oral LTD4 receptor antagonist ICI 204,219. | Q41199570 | ||
| Leukotrienes in the pathogenesis of asthma | Q41355232 | ||
| Challenge studies of a leukotriene receptor antagonist | Q41355249 | ||
| Worldwide clinical experience with the first marketed leukotriene receptor antagonist | Q41355257 | ||
| Single dose pharmacokinetics, safety and tolerability of MK-0476, a new leukotriene D4-receptor antagonist, in healthy volunteers | Q41826760 | ||
| Evening dosing is associated with higher plasma concentrations of pranlukast, a leukotriene receptor antagonist, in healthy male volunteers | Q42254890 | ||
| Dose-dependent mediation of leukotriene D4-induced airway microvascular leakage and bronchoconstriction in the guinea pig | Q42277463 | ||
| Effects of 6 weeks of therapy with oral doses of ICI 204,219, a leukotriene D4 receptor antagonist, in subjects with bronchial asthma. ACCOLATE Asthma Trialists Group | Q42284265 | ||
| The leukotriene-antagonist ICI-204,219 inhibits the early airway reaction to cumulative bronchial challenge with allergen in atopic asthmatics | Q42285428 | ||
| Inhibition of leukotriene D4-induced bronchoconstriction in subjects with asthma: a concentration-effect study of ICI 204,219. | Q42286335 | ||
| The protective effect of inhaled leukotriene D4 receptor antagonist ICI 204,219 against exercise-induced asthma | Q42288897 | ||
| Potent leukotriene D4 receptor antagonist ICI 204,219 given by the inhaled route inhibits the early but not the late phase of allergen-induced bronchoconstriction | Q42288898 | ||
| Zafirlukast for symptomatic mild-to-moderate asthma: a 13-week multicenter study. The Zafirlukast Trialists Group | Q42546418 | ||
| Therapeutic effect of pranlukast, a selective cysteinyl leukotriene receptor antagonist, on bronchial asthma | Q42547582 | ||
| Combined antagonism of leukotrienes and histamine produces predominant inhibition of allergen-induced early and late phase airway obstruction in asthmatics | Q42549036 | ||
| Effectiveness of the leukotriene receptor antagonist zafirlukast for mild-to-moderate asthma. A randomized, double-blind, placebo-controlled trial. | Q42551235 | ||
| A controlled trial of the effect of the 5-lipoxygenase inhibitor, zileuton, on lung inflammation produced by segmental antigen challenge in human beings | Q42556664 | ||
| Effect of treatment with zileuton, a 5-lipoxygenase inhibitor, in patients with asthma. A randomized controlled trial. Zileuton Clinical Trial Group | Q42556993 | ||
| Release of leukotrienes in patients with bronchial asthma | Q43414768 | ||
| Montelukast once daily inhibits exercise-induced bronchoconstriction in 6- to 14-year-old children with asthma | Q46488895 | ||
| Pharmacokinetics, bioavailability, and safety of montelukast sodium (MK-0476) in healthy males and females. | Q51024973 | ||
| The pharmacokinetics of zileuton in healthy young and elderly volunteers. | Q51034430 | ||
| The effect of food on the pharmacokinetics of zileuton. | Q51591572 | ||
| Pharmacokinetics and pharmacodynamics of zileuton after oral administration of single and multiple dose regimens of zileuton 600mg in healthy volunteers. | Q51591577 | ||
| Experimental asthma developed by room air contamination with cockroach allergen. | Q52551419 | ||
| Montelukast, a potent leukotriene receptor antagonist, causes dose-related improvements in chronic asthma. Montelukast Asthma Study Group. | Q53573791 | ||
| Effects of montelukast (MK-0476), a new potent cysteinyl leukotriene (LTD4) receptor antagonist, in patients with chronic asthma. | Q53983069 | ||
| Leukotriene receptor antagonists: clinical effects. | Q55686747 | ||
| THE LIBERATION OF A SLOW-REACTING SMOOTH MUSCLE-STIMULATING SUBSTANCE IN ANAPHYLAXIS | Q56432304 | ||
| The Pivotal Role of 5-Lipoxygenase Products in the Reaction of Aspirin-sensitive Asthmatics to Aspirin | Q57240791 | ||
| Effect of the oral leukotriene antagonist, ICI 204,219, on antigen-induced bronchoconstriction in subjects with asthma | Q68121522 | ||
| Exercise-Induced Urinary Excretion of Leukotriene E4 in Children with Atopic Asthma | Q68254708 | ||
| Effect of cysteinyl-leukotriene receptor antagonist ICI 204.219 on allergen-induced bronchoconstriction and airway hyperreactivity in atopic subjects | Q68293935 | ||
| Inhibition of platelet-activating factor-induced bronchoconstriction by the leukotriene D4 receptor antagonist ICI 204,219 | Q70530056 | ||
| Effect of a leukotriene antagonist, ONO-1078, on bronchial hyperresponsiveness in patients with asthma | Q70726803 | ||
| Pharmacokinetic interactions between zileuton and prednisone | Q71056758 | ||
| The effect of mild or moderate hepatic impairment (cirrhosis) on the pharmacokinetics of zileuton | Q71056781 | ||
| Effect of zileuton on theophylline pharmacokinetics | Q71056792 | ||
| The pharmacokinetics of single oral doses of zileuton 200 to 800mg, its enantiomers, and its metabolites, in normal healthy volunteers | Q71056802 | ||
| P433 | issue | 2 | |
| P921 | main subject | asthma | Q35869 |
| P304 | page(s) | 77-88 | |
| P577 | publication date | 1999-05-01 | |
| P1433 | published in | Pediatric Allergy & Immunology | Q14064731 |
| P1476 | title | New perspectives for asthma treatment: anti-leukotriene drugs | |
| P478 | volume | 10 |
| Q34240893 | Antileukotrienes in asthma: present situation |
| Q35123390 | Benefit-risk assessment of antileukotrienes in the management of asthma. |
| Q45014739 | Comparative effect of triamcinolone, nedocromil and montelukast on asthma control in children: A randomized pragmatic study |
| Q59481265 | Copper complexes of non-steroidal anti-inflammatory drugs: an opportunity yet to be realized |
| Q31027582 | Differential inhibitory effects of CysLT(1) receptor antagonists on P2Y(6) receptor-mediated signaling and ion transport in human bronchial epithelia |
| Q45067692 | Effects of a cysteinyl leukotriene receptor antagonist on eosinophil recruitment in experimental allergic rhinitis |
| Q34767412 | Exercise-induced bronchoconstriction |
| Q44784902 | Exhaled breath condensate eicosanoids and sputum eosinophils in asthmatic children: a pilot study |
| Q79429562 | Montelukast with desloratadine or levocetirizine for the treatment of persistent allergic rhinitis |
| Q34579642 | Stereoselective pharmacokinetics and pharmacodynamics of anti-asthma agents |
Search more.